Clinical trial results unveiled today at ACTRIMS Forum 2026 suggest that fenebrutinib may be a novel and effective treatment option for people living with primary progressive multiple sclerosis. In this exclusive episode providing the first expert discussion of the complete dataset, FENtrepid trial leads Prof. Amit Bar-Or (University of Pennsylvania) and Dr. Stephen Hauser (University of California San Francisco) break down what the fenebrutinib results really show. Together, they explore:

• Why BTK inhibition is uniquely positioned to address progressive MS biology
• How fenebrutinib compared to ocrelizumab in the Phase 3 FENtrepid PPMS trial
• What the data suggest for patients with non-relapsing, chronic disease

Listen for a deep dive into the science and the clinical implications.

Editorial Note: At 21:49, the discussion refers to Müller cells. The correct term is Kupffer cells.

Download the transcript